Harvard Bioscience
HBIO • NASDAQ
Harvard Bioscience is a medical - instruments & supplies company in the healthcare sector trading on NASDAQ, led by CEO John Duke, with a market cap of $21.8M.
CEOJohn Duke
Market Cap$21.8M
Medical - Instruments & Supplies
Healthcare
Employees416.0
Websiteharvardbioscience.com
Next Earnings
Upcoming earnings announcement for Harvard Bioscience
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.10
Revenue Estimate
$21.0M
Earnings History
Past 12 earnings reports for Harvard Bioscience
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Q4 2025 | $0.00Est: $0.30 | -100.0% | $23.7MEst: $23.1M | +2.7% |  10-K |
| Nov 6, 2025 | Q3 2025 | $0.00Est: $0.01 | -100.0% | $20.6MEst: $20.0M | +3.0% | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.01Est: -$0.02 | +50.0% | $20.5MEst: $18.8M | +9.1% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.01Est: -$0.04 | +75.0% | $21.8MEst: $19.2M | +13.4% | 10-Q |
| Mar 12, 2025 | Q4 2024 | $0.06Est: $0.05 | +20.0% | $24.6MEst: $24.2M | +1.7% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.02Est: $0.03 | -166.7% | $22.0MEst: $25.3M | -13.2% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $0.00Est: $0.05 | -100.0% | $23.1MEst: $26.4M | -12.5% | 10-Q |
| May 7, 2024 | Q1 2024 | $0.02Est: $0.02 | 0.0% | $24.5MEst: $25.8M | -5.0% | 10-Q |
| Mar 7, 2024 | Q4 2023 | $0.04Est: $0.05 | -20.0% | $28.2MEst: $29.1M | -3.3% | 10-K |
| Nov 7, 2023 | Q3 2023 | $0.01Est: $0.04 | -75.0% | $25.4MEst: $28.0M | -9.5% | — |
| Aug 8, 2023 | Q2 2023 | $0.04Est: $0.05 | -20.0% | $28.8MEst: $29.5M | -2.5% | 10-Q |
| Apr 25, 2023 | Q1 2023 | $0.06Est: $0.05 | +20.0% | $30.0MEst: $28.9M | +3.9% | — |